TY - JOUR
T1 - The biology of the sodium iodide symporter and its potential for targeted gene delivery
AU - Hingorani, M.
AU - Spitzweg, C.
AU - Vassaux, G.
AU - Newbold, K.
AU - Melcher, A.
AU - Pandha, H.
AU - Vile, R.
AU - Harrington, K.
PY - 2010/3
Y1 - 2010/3
N2 - The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.
AB - The sodium iodide symporter (NIS) is responsible for thyroidal, salivary, gastric, intestinal and mammary iodide uptake. It was first cloned from the rat in 1996 and shortly thereafter from human and mouse tissue. In the intervening years, we have learned a great deal about the biology of NIS. Detailed knowledge of its genomic structure, transcriptional and post-transcriptional regulation and pharmacological modulation has underpinned the selection of NIS as an exciting approach for targeted gene delivery. A number of in vitro and in vivo studies have demonstrated the potential of using NIS gene therapy as a means of delivering highly conformal radiation doses selectively to tumours. This strategy is particularly attractive because it can be used with both diagnostic (99mTc, 125I, 124I) and therapeutic ( 131I, 186Re, 188Re, 211At) radioisotopes and it lends itself to incorporation with standard treatment modalities, such as radiotherapy or chemoradiotherapy. In this article, we review the biology of NIS and discuss its development for gene therapy.
KW - Adenovirus
KW - Gene therapy
KW - Measles virus
KW - Radioiodide
KW - Radiotherapy
KW - Sodium iodide symporter
UR - http://www.scopus.com/inward/record.url?scp=77950687906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950687906&partnerID=8YFLogxK
U2 - 10.2174/156800910791054194
DO - 10.2174/156800910791054194
M3 - Review article
C2 - 20201784
AN - SCOPUS:77950687906
SN - 1568-0096
VL - 10
SP - 242
EP - 267
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
IS - 2
ER -